TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9209724
Drug: Successful tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Successful tapering off medication
Study: 3042317
Drug: Clofibrate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (1.5 g/day)
Study: 31679120
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Oxycodone Tamper-Resistant Tablet (OTR)
Study: 31679120
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg OXYCONTIN® (OXY)
Study: 30942008
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after treatment (Observation group)
Study: 28268074
Drug: Inactivated zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated zoster vaccine (ZVIN), 4-dose regimen (∼30 days between doses)
Study: 17012141
Drug: Oral beta‐1,3/1,6‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta‐1,3/1,6‐glucan 700 mg (Group 1)
Study: 17012141
Drug: Oral beta‐1,3/1,6‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta‐1,3/1,6‐glucan 1400 mg (Group 2)
Study: 12709037
Drug: Aggressive multiple-infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive multiple-infusion episode-based protocol
Study: 12709037
Drug: Individualized escalating
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized escalating dose and frequency of routine replacement infusions of factor concentrate
Study: 7015795
Drug: Captopril (75-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75-450 mg daily)
Study: 7015795
Drug: Captopril (75-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75-450 mg daily) + Hydrochlorothiazide (50-100 mg daily)
Study: 7015795
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Hydrochlorothiazide (50-100 mg daily)
Study: 28486709
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT; lozenge, patch, both)
Study: 28486709
Drug: Bupropion (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (alone or with nicotine lozenge)
Study: 20717875
Drug: HMC05 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMC05 (500 mg tablets, 3 times daily for 4 weeks)
Study: 20717875
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg tablets, 3 times daily for 4 weeks)
Study: 15705087
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic alpha-blocker
Study: 12385927
Drug: Prophylactic alpha-blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic alpha-blockers
Study: 15705087
Drug: Supplemental radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental radiotherapy and/or androgen deprivation therapy
Study: 12851876
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10‐mg therapy for 48 weeks
Study: 8740244
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg for 1 month, 20 mg for 1 month, 40 mg for 4 months
Study: 6761123
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release oxprenolol 160 mg twice daily
Study: 30863632
Drug: High-dose IQP-AE-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IQP-AE-103
Study: 30863632
Drug: Low-dose IQP-AE-103
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IQP-AE-103
Study: 28209040
Drug: Essential diagnosis
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential diagnosis and treatment services
Study: 26022508
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) - bolus dose of 0.5 µg·kg‐1 within 10 min, maintenance dose of 0.5 µg·kg‐1·h‐1
Study: 26022508
Drug: Etomidate (ETO)
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate (ETO) - bolus dose of 0.3 mg·kg‐1 without maintenance dose
Study: 22284296
Drug: Continuous forces
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 2 weeks
Study: 22284296
Drug: Continuous forces
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 3 weeks
Study: 22284296
Drug: Continuous forces
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous forces (150 g)
Study: 19573637
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis (DTwP//Hib+oral poliomyelitis vaccine [OPV]) combination vaccine
Study: 17877658
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram
Study: 72237
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide (100 mg four times daily)
Study: 31374589
Drug: Coronary artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary artery bypass grafting (CABG) with optimal medical therapy (OMT)
Study: 23388527
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (3 times per week for 6 months)
Study: 27737664
Drug: naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 1000 mg
Study: 19567491
Drug: In-hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital treatment of OSA using auto-adjusting positive airway pressure along with standard treatment of ADHF
Study: 19567491
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for ADHF
Study: 17012419
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg single dose)
Study: 15268624
Drug: Twice-weekly humanised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly humanised anti-IL-6R monoclonal antibody (MRA)
Study: 1604411
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of CN-100 at a dose of 150 mg
Study: 1604411
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of CN-100 at a dose of 300 mg
Study: 1604411
Drug: Repetitive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive oral administration of CN-100 at a daily dose of 300 mg
Study: 1604411
Drug: Repetitive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive oral administration of CN-100
Study: 3728891
Drug: Physostigmine 2
Normalized name: PHYSostigmine 2 mg/5 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 2 mg i.v. prior to extubation
Study: 29240641
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin injections
Study: 26129928
Drug: Antioxidant group
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant group (500 mg of vitamin C and 117.5 mg vitamin E before and after training)
Study: 12393113
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 4.3 microg.kg(‐1) plus IV 0.9% saline (Group 1)
Study: 12393113
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 4.3 microg.kg(‐1) plus IV buprenorphine 1.3 microg.kg(‐1) (Group 3)
Study: 10207203
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of basic fibroblast growth factor (bFGF) within hours after the onset of ischemia
Study: 10207203
Drug: Intracisternal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracisternal administration of basic fibroblast growth factor (bFGF) starting at one day after ischemia
Study: 10207203
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of basic fibroblast growth factor (bFGF) as a recovery-promoting agent in subacute stroke
Study: 2645756
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg once daily
Study: 7553405
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg daily (one-year open treatment)
Study: 373489
Drug: Methazolamide (Neptazane)
Normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methazolamide (Neptazane) 50 mg p.o.
Study: 373489
Drug: Methazolamide (Neptazane)
Normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methazolamide (Neptazane) 100 mg p.o.
Study: 31146741
Drug: NS-21 cream
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS-21 cream applied three times per day during RT or CCRT
Study: 31146741
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment applied three times per day during RT or CCRT
Study: 31146741
Drug: NS-21 cream
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS-21 cream
Study: 27241125
Drug: Subcutaneous Adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Adipose Tissue (SAT)
Study: 24935272
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) at a dose of 5 μg/kg subcutaneously every 12 hours for 5 consecutive days (group A)
Study: 24935272
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) plus G-CSF (group A)
Study: 24935272
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) alone (group B)
Study: 20849244
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (target 13.0-15.0 g/dL; Group 1)
Study: 20849244
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (target 10.5-11.5 g/dL; Group 2)
Study: 16716541
Drug: Swaddled babies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swaddled babies kept in the nursery with breast-milk supplements
Study: 16716541
Drug: Swaddled babies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swaddled babies receiving supplements
Study: 16224157
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil monotherapy
Study: 16224157
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ongoing lamivudine
Study: 9483448
Drug: Cimetidine 50
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 50 mg/kg administered intravenously just prior to IHCP (cimetidine group)
Study: 710028
Drug: Naproxen alone
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen alone (500 mg single oral dose)
Study: 710028
Drug: Naproxen with
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen with probenecid (500 mg 4 times a day)
Study: 710028
Drug: Naproxen with
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen with probenecid (250 mg twice daily for 8 days)
Study: 31707266
Drug: Recommended Usual
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended Usual Care (R‐UC): 8 weeks of nicotine patch plus brief counseling
Study: 31707266
Drug: Abstinence‐Optimized Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence‐Optimized Treatment (A‐OT): 3 weeks of pre‐quit mini‐lozenges, 26 weeks of nicotine patch plus mini‐lozenges, 11 counseling contacts, and 7‐11 automated reminders
Study: 24158333
Drug: Standard implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implant (4-mm platform)
Study: 9048709
Drug: Mitoxantrone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (20 mg IV monthly) and methylprednisolone (1 g IV monthly)
Study: 3525022
Drug: Oral terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline, 5 mg qid
Study: 3525022
Drug: Inhaled terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline, 400 micrograms qid
Study: 3525022
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets or metered-dose inhalers)
Study: 31286733
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and care (Control group)
Study: 28190788
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg kg−1 hour−1
Study: 28190788
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg kg−1 hour−1
Study: 21502549
Drug: Nadroparin (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (subcutaneous administration for 6 weeks: 2 weeks at therapeutic dose, 4 weeks at half therapeutic dose)
Study: 15575830
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (0.5%) without lacrimal occlusion
Study: 9072665
Drug: Immunomodulating drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating drug of bacterial derivation
Study: 1476466
Drug: Quinine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine infusion regimen (8 mg of quinine base/kg of body weight over 1 h followed by 8 mg of base/kg over 7 h, then 8 mg/kg over 8 h 3 times daily for 3 days)
Study: 1476466
Drug: Classical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical regimen (8 mg of base/kg over 8 h, 3 times daily for 3 days)
Study: 6439759
Drug: Oral digoxin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral digoxin, 0.5 mg daily, on days 10 through 22 of a menstrual cycle
Study: 6439759
Drug: Intravenous digoxin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous digoxin, 0.5 mg daily for days 7 through 21 of a menstrual cycle
Study: 30820517
Drug: Creatine-High (CR-H;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine-High (CR-H; 0.3 g/kg/day of creatine + 0.1 g/kg/day of maltodextrin)
Study: 30820517
Drug: Creatine-Moderate (CR-M;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine-Moderate (CR-M; 0.1 g/kg/day of creatine + 0.3 g/kg/day of maltodextrin)
Study: 30820517
Drug: Placebo (PLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA; 0.4 g/kg/day of maltodextrin)
Study: 3105472
Drug: verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (5 mg)
Study: 29898437
Drug: heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin (5,000 IU)
Study: 20130407
Drug: Specific diet
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific diet based on IgG antibodies against food antigens
Study: 17919542
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine patch applied for 3 days
Study: 17919542
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine patch applied for 4 days
Study: 8527287
Drug: Tolcapone (10-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (10-800 mg)
Study: 6230173
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg bid for 14 days)
Study: 30835822
Drug: Intra-operative dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative dexmedetomidine (0.5 µg.kg-1 bolus followed by 0.4 µg.kg-1.hr-1 infusion)
Study: 30701937
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (omeprazole, amoxicillin, clarithromycin)
Study: 30701937
Drug: Four-component therapy
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-component therapy with bismuth (omeprazole, tetracycline, metronidazole, bismuth tricalium dicitrate)
Study: 30701937
Drug: Hybrid scheme
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid scheme (first 5 days: omeprazole and amoxicillin, next 5 days: omeprazole, amoxicillin, clarithromycin, metronidazole)
Study: 19230758
Drug: Auto-CPAP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-CPAP titration (optimal pressure 7.0 cmH2O)
Study: 27134145
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment (esomeprazole 40mg, amoxicillin 1g/bid for 5 days, followed by 5 days of esomeprazole 40mg, clarithromycin 500mg and metronidazole 500mg bid for 10 days)
Study: 27134145
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (same drugs as concomitant but taken sequentially)
Study: 10078856
Drug: 2% aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% aminophylline cream (AC)
Study: 10078856
Drug: no cream
Normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no cream (NC)
Study: 10078856
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream (PC)
Study: 28335664
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy intervention (CBTi)
Study: 21832111
Drug: Combined (Clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (Clomiphene citrate + Metformin)
Study: 11715169
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (0.5 mL containing A/Wuhan/359/95 (H3N2), A/Texas/36/91 (H1N1), B/Beijing/184/93)
Study: 9570259
Drug: 15 or
Normalized name: Oseni 25/15 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 or 30 mg lansoprazole/day
Study: 9570259
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole/day
Study: 8056998
Drug: lorazepam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 0.75 mg
Study: 8056998
Drug: lorazepam up
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lorazepam up to 1.5 mg
Study: 3383875
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg b.i.d. (n = 154)
Study: 31127676
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.8 mg daily for 3 months
Study: 28715540
Drug: Pyridoxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (200 mg daily for a maximum of 8 cycles of capecitabine)
Study: 28715540
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for a maximum of 8 cycles of capecitabine)
Study: 20185003
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine response (10 microg/kg/min)
Study: 18388122
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate (CC) 500 mg
Study: 18388122
Drug: Sevelamer Hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer Hydrochloride (SEV) 800 mg
Study: 15898218
Drug: Automated system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated system with recommendation to prescribe angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers
Study: 12534414
Drug: Alosetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron (1 mg b.d.)
Study: 10368502
Drug: Prepidil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepidil (0.5 mg intracervically every 6 hours)
Study: 1702812
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/day for 3 days)
Study: 6276584
Drug: β-endorphin 2
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-endorphin 2 mg intrathecally
Study: 6276584
Drug: morphine HCl
Normalized name: morphine HCl
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine HCl 0.2 mg intrathecally
Study: 31449470
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by standard chemoradiation (CRT)
Study: 23715821
Drug: Sertaconazole 2
Normalized name: sertaconazole 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 2 % cream
Study: 23715821
Drug: Pimecrolimus 1
Normalized name: pimecrolimus 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1 % cream
Study: 16923461
Drug: Clopidogrel 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 900 mg loading dose